Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Managing locally advanced bladder cancer.

Jan Lehmann1, Margitta Retz, Stefan Siemer

  • 1Department of Urology and Pediatric Urology, Saarland University, Kirrberger Strasse, 66421 Homburg/Saar, Germany. jan.lehmann@uniklinik-saarland.de

Expert Review of Anticancer Therapy
|December 31, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pilot Survey about the perspective on Generation Z among European leaders in Urology: Challenges in educating Generation Z.

Urologia internationalis·2026
Same author

Expression of progranulin (GP88) protein appears as an independent prognostic factor for clinical progression in high-risk prostate cancer patients.

Scientific reports·2026
Same author

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Digital Therapeutic FEMANEA® for Women with Stress and Mixed Urinary Incontinence: A Randomized Controlled Pilot Study.

International urogynecology journal·2026
Same author

[Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus].

Urologie (Heidelberg, Germany)·2026
Same author

GPS1 Exon 9 Mutations Represent a Rare Genetic Event in Penile Squamous Cell Carcinoma Pathogenesis.

International journal of molecular sciences·2026

Radical cystectomy can cure locally advanced bladder cancer, but systemic progression remains common. Adjuvant chemotherapy is studied to improve outcomes, yet neoadjuvant versus adjuvant chemotherapy superiority is debated.

Area of Science:

  • Uro-oncology
  • Surgical oncology
  • Medical oncology

Background:

  • Locally advanced bladder cancer (stages pT3a, pT3b, pT4a, or lymph node involvement) is treatable with radical cystectomy.
  • Despite curative intent surgery, over 50% of patients experience disease recurrence within five years.
  • Systemic progression post-cystectomy necessitates exploring effective adjuvant therapies.

Purpose of the Study:

  • To review the evidence for systemic chemotherapy as an adjunctive treatment for locally advanced bladder cancer.
  • To compare the efficacy of neoadjuvant versus adjuvant chemotherapy in improving patient outcomes after radical cystectomy.
  • To address the ongoing debate regarding the optimal timing of chemotherapy administration.

Main Methods:

  • Systematic review of randomized Phase III trials evaluating adjunctive chemotherapy in conjunction with radical cystectomy.

Related Experiment Videos

  • Analysis of data from over a dozen trials investigating neoadjuvant and adjuvant chemotherapy regimens.
  • Comparative assessment of treatment outcomes based on chemotherapy timing.

    • Main Results:

    • Radical cystectomy is a curative option for locally advanced bladder cancer.
    • Significant rates of systemic progression occur within five years post-cystectomy.
    • Multiple Phase III trials have investigated neoadjuvant and adjuvant chemotherapy, but a consensus on superiority is lacking.

    Conclusions:

    • Adjunctive systemic chemotherapy is a critical area of research for improving survival in locally advanced bladder cancer.
    • The optimal timing (neoadjuvant vs. adjuvant) of systemic chemotherapy remains a subject of ongoing clinical debate and research.
    • Further research is needed to definitively establish the most effective chemotherapeutic strategy to prevent systemic progression.